Skip to main content

Table 3 Hematological and non-hematological adverse events (n = 234)

From: Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients

Events

Grade of chemotherapy toxicity (No (%))

Grade 0

Grade 1

Grade 2

Grade 3

Grade 4

Grade 3 + 4 (%)

Hematological adverse events

Anemia

29(12.4)

153(65.4)

45(19.2)

7(3.0)

3

Neutropenia

94(40.2)

41(17.5)

67(28.6)

31(13.2)

1(0.4)

13.6

Thrombocytopenia

150(64.1)

73(31.2)

10(4.3)

1(0.4)

0.4

Febrile neutropenia

233(99.6)

1(0.4)

0.4

Leucopenia

125(53.4)

86(36.8)

22(9.4)

1(0.4)

0.4

Total

14(6.0)

95(40.6)

87(37.2)

37(15.8)

1(0.4)

16.2

Non-hematological adverse events

Anorexia

142(60.7)

61(26.1)

28(12.0)

3(1.3)

1.3

Nausea

165(70.5)

51(21.8)

17(7.3)

1(0.4)

0.4

Vomiting

206(88.0)

16(6.8)

11(4.7)

1(0.4)

0.4

Diarrhea

119(50.9)

58(24.8)

43(18.4)

14(6.0)

6

Constipation

213(91.0)

19(8.1)

2(0.9)

0

Abdominal pain

183(78.2)

31(13.2)

10(4.3)

10(4.3)

4.3

Stomatitis

191(81.6)

26(11.1)

15(6.4)

2(0.9)

0.9

Hand-foot syndrome

200(85.5)

27(11.5)

6(2.6)

1(0.4)

0.4

Fatigue

194(82.9)

35(15.0)

4(1.7)

1(0.4)

0.4

Hyperpigmentation

183(78.2)

47(20.1)

3(1.3)

1(0.4)

0.4

Rash

215(91.9)

14(6.0)

3 (1.3)

2(0.9)

0.8

Elevated AST/ALT level

149(63.7)

77(32.9)

5(2.1)

3(1.3)

1.3

Elevated bilirubin level

89(38.0)

99(42.3)

43(18.4)

3(1.3)

1.3

Elevated creatinine level

230(98.3)

4(1.7)

0

Total

10(4.3)

99(23.1)

86(36.8)

39(16.7)

16.7

  1. AST/ALT aspartate transaminase/alanine transaminase